This company has been acquired
PRDS Stock Overview
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pardes Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.16 |
| 52 Week High | US$3.67 |
| 52 Week Low | US$0.75 |
| Beta | 0.42 |
| 1 Month Change | 2.37% |
| 3 Month Change | 14.29% |
| 1 Year Change | -40.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.98% |
Recent News & Updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20Recent updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21Shareholder Returns
| PRDS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.5% | 0.4% | 1.0% |
| 1Y | -40.0% | 0.9% | 21.9% |
Return vs Industry: PRDS underperformed the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: PRDS underperformed the US Market which returned 11.7% over the past year.
Price Volatility
| PRDS volatility | |
|---|---|
| PRDS Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRDS has not had significant price volatility in the past 3 months.
Volatility Over Time: PRDS's weekly volatility has decreased from 12% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 57 | Tom Wiggans | www.pardesbio.com |
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Pardes Biosciences, Inc. Fundamentals Summary
| PRDS fundamental statistics | |
|---|---|
| Market cap | US$131.19m |
| Earnings (TTM) | -US$76.14m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs PRDS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRDS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$76.14m |
| Earnings | -US$76.14m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PRDS perform over the long term?
See historical performance and comparison